Scholarlink

Background/objectives <p>This study reported real-world visual acuity (VA), treatment patterns, and ocular safety outcomes from patients with macular oedema secondary to branch, central, or hemi-retinal vein occlusion (BRVO, CRVO, HRVO) treated with anti-vascular endothelial growth factor (VEGF).</p> Methods <p>Data were collected from Medisoft electronic medical records across 16 NHS ophthalmology sites in England over 60 months.</p> Results <p>3511/3465 eyes/patients with BRVO and 3568/3514 eyes/patients with CRVO or HRVO were included; &lt;2% of patients had bilateral RVO and had both eyes included. VA change from index anti-VEGF treatment was lower with longer follow-up. In BRVO eyes, mean (95% CI) change in VA from index was +11.2 (10.6, 11.7) approximate Early Treatment Diabetic Retinopathy Study (ETDRS) letters at Month (M)6 and +8.3 (6.7, 10.0) at M60. Mean (95% CI) change in VA for CRVO/HRVO eyes was +11.5 (10.7, 12.3) approximate ETDRS letters at M6 and +7.0 (4.8, 9.2) at M60. Eyes receiving more injections displayed greater average VA gains. Median (Q1–Q3) annual number of anti-VEGF injections was lower in BRVO and CRVO/HRVO eyes with longer follow-up: M12, 7.0 (5.0–8.0) and 6.0 (4.0–8.0); M60, 2.0 (0.0–5.0) and 1.0 (0.0–5.0). Ocular safety outcome incidence through 60 months was low (endophthalmitis, retinal tears, and retinal detachment &lt;1%).</p> Conclusions <p>VA improvements were observed soon after anti-VEGF treatment, but were lower with longer follow-up through 60 months, alongside lower annual injection numbers, suggesting that current single-target intravitreal anti-VEGFs may not be sufficiently durable for long-term RVO management in routine practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Treatment patterns and long-term outcomes in anti-VEGF-treated macular oedema secondary to retinal vein occlusion: a retrospective observational study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月14日

查看全文
  • Christiana Dinah,
  • Melanie Dodds,
  • Andrew Lotery,
  • Serena Salvatore,
  • Emily Fletcher,
  • Alice V. R. Lake,
  • Antony Parker,
  • Liliana Paris Pereira,
  • Anne-Cecile Retiere,
  • Insaf Saffar,
  • Pablo Arrisi,
  • Indra Dias,
  • Richard Antcliff,
  • Faruque Ghanchi,
  • James Talks,
  • Chris Brand,
  • Aires Lobo,
  • Louise Downey,
  • Colin Jones,
  • Sheena George,
  • Ashish Patwardhan,
  • Yinka Osoba,
  • Balasubramanian Ramasamy,
  • Gloria C. Chi

摘要

Background/objectives

This study reported real-world visual acuity (VA), treatment patterns, and ocular safety outcomes from patients with macular oedema secondary to branch, central, or hemi-retinal vein occlusion (BRVO, CRVO, HRVO) treated with anti-vascular endothelial growth factor (VEGF).

Methods

Data were collected from Medisoft electronic medical records across 16 NHS ophthalmology sites in England over 60 months.

Results

3511/3465 eyes/patients with BRVO and 3568/3514 eyes/patients with CRVO or HRVO were included; <2% of patients had bilateral RVO and had both eyes included. VA change from index anti-VEGF treatment was lower with longer follow-up. In BRVO eyes, mean (95% CI) change in VA from index was +11.2 (10.6, 11.7) approximate Early Treatment Diabetic Retinopathy Study (ETDRS) letters at Month (M)6 and +8.3 (6.7, 10.0) at M60. Mean (95% CI) change in VA for CRVO/HRVO eyes was +11.5 (10.7, 12.3) approximate ETDRS letters at M6 and +7.0 (4.8, 9.2) at M60. Eyes receiving more injections displayed greater average VA gains. Median (Q1–Q3) annual number of anti-VEGF injections was lower in BRVO and CRVO/HRVO eyes with longer follow-up: M12, 7.0 (5.0–8.0) and 6.0 (4.0–8.0); M60, 2.0 (0.0–5.0) and 1.0 (0.0–5.0). Ocular safety outcome incidence through 60 months was low (endophthalmitis, retinal tears, and retinal detachment <1%).

Conclusions

VA improvements were observed soon after anti-VEGF treatment, but were lower with longer follow-up through 60 months, alongside lower annual injection numbers, suggesting that current single-target intravitreal anti-VEGFs may not be sufficiently durable for long-term RVO management in routine practice.